 | • レポートコード：MRC2-11QY01516 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は高脂血症処方薬のグローバル市場について調査・分析したレポートです。種類別（HMG COAレダクターゼ阻害剤、フィブリン酸誘導体、ニコチン酸、胆汁酸封鎖剤、コレステロール吸収阻害剤、併用薬物療法）市場規模、用途別（病院・クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別高脂血症処方薬の競争状況、市場シェア ・世界の高脂血症処方薬市場：種類別市場規模 2015年-2020年（HMG COAレダクターゼ阻害剤、フィブリン酸誘導体、ニコチン酸、胆汁酸封鎖剤、コレステロール吸収阻害剤、併用薬物療法） ・世界の高脂血症処方薬市場：種類別市場規模予測 2021年-2026年（HMG COAレダクターゼ阻害剤、フィブリン酸誘導体、ニコチン酸、胆汁酸封鎖剤、コレステロール吸収阻害剤、併用薬物療法） ・世界の高脂血症処方薬市場：用途別市場規模 2015年-2020年（病院・クリニック） ・世界の高脂血症処方薬市場：用途別市場規模予測 2021年-2026年（病院・クリニック） ・北米の高脂血症処方薬市場分析：米国、カナダ ・ヨーロッパの高脂血症処方薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの高脂血症処方薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の高脂血症処方薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの高脂血症処方薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、Eli Lilly、GlaxoSmithKline Pharmaceuticals、Isis Pharmaceuticals、Merck、Dr.Reddy's Laboratories、Immuron Limited、Esperion Therapeutics、Pfizer、Formac Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Hyperlipidemia Prescription Drugs Market
The global Hyperlipidemia Prescription Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hyperlipidemia Prescription Drugs Scope and Market Size
Hyperlipidemia Prescription Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hyperlipidemia Prescription Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hyperlipidemia Prescription Drugs market is segmented into
HMG COA Reductase Inhibitors
Fibric Acid Derivatives
Nicotinic Acid
Bile Acid Sequestrating Agents
Cholesterol Absorption Inhibitors
Combination Drug Therapy
Segment by Application, the Hyperlipidemia Prescription Drugs market is segmented into
Hospital
Clinic
Regional and Country-level Analysis
The Hyperlipidemia Prescription Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hyperlipidemia Prescription Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hyperlipidemia Prescription Drugs Market Share Analysis
Hyperlipidemia Prescription Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hyperlipidemia Prescription Drugs business, the date to enter into the Hyperlipidemia Prescription Drugs market, Hyperlipidemia Prescription Drugs product introduction, recent developments, etc.
The major vendors covered:
Amgen
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Isis Pharmaceuticals
Merck
Dr.Reddy’s Laboratories
Immuron Limited
Esperion Therapeutics
Pfizer
Formac Pharmaceuticals
1 Study Coverage
1.1 Hyperlipidemia Prescription Drugs Product Introduction
1.2 Market Segments
1.3 Key Hyperlipidemia Prescription Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hyperlipidemia Prescription Drugs Market Size Growth Rate by Type
1.4.2 HMG COA Reductase Inhibitors
1.4.3 Fibric Acid Derivatives
1.4.4 Nicotinic Acid
1.4.5 Bile Acid Sequestrating Agents
1.4.6 Cholesterol Absorption Inhibitors
1.4.7 Combination Drug Therapy
1.5 Market by Application
1.5.1 Global Hyperlipidemia Prescription Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hyperlipidemia Prescription Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hyperlipidemia Prescription Drugs Revenue 2015-2026
2.1.2 Global Hyperlipidemia Prescription Drugs Sales 2015-2026
2.2 Global Hyperlipidemia Prescription Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hyperlipidemia Prescription Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hyperlipidemia Prescription Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hyperlipidemia Prescription Drugs Competitor Landscape by Players
3.1 Hyperlipidemia Prescription Drugs Sales by Manufacturers
3.1.1 Hyperlipidemia Prescription Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hyperlipidemia Prescription Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hyperlipidemia Prescription Drugs Revenue by Manufacturers
3.2.1 Hyperlipidemia Prescription Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hyperlipidemia Prescription Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hyperlipidemia Prescription Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hyperlipidemia Prescription Drugs Revenue in 2019
3.2.5 Global Hyperlipidemia Prescription Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hyperlipidemia Prescription Drugs Price by Manufacturers
3.4 Hyperlipidemia Prescription Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hyperlipidemia Prescription Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hyperlipidemia Prescription Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hyperlipidemia Prescription Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hyperlipidemia Prescription Drugs Market Size by Type (2015-2020)
4.1.1 Global Hyperlipidemia Prescription Drugs Sales by Type (2015-2020)
4.1.2 Global Hyperlipidemia Prescription Drugs Revenue by Type (2015-2020)
4.1.3 Hyperlipidemia Prescription Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hyperlipidemia Prescription Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hyperlipidemia Prescription Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hyperlipidemia Prescription Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hyperlipidemia Prescription Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hyperlipidemia Prescription Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hyperlipidemia Prescription Drugs Market Size by Application (2015-2020)
5.1.1 Global Hyperlipidemia Prescription Drugs Sales by Application (2015-2020)
5.1.2 Global Hyperlipidemia Prescription Drugs Revenue by Application (2015-2020)
5.1.3 Hyperlipidemia Prescription Drugs Price by Application (2015-2020)
5.2 Hyperlipidemia Prescription Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hyperlipidemia Prescription Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hyperlipidemia Prescription Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hyperlipidemia Prescription Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hyperlipidemia Prescription Drugs by Country
6.1.1 North America Hyperlipidemia Prescription Drugs Sales by Country
6.1.2 North America Hyperlipidemia Prescription Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hyperlipidemia Prescription Drugs Market Facts & Figures by Type
6.3 North America Hyperlipidemia Prescription Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hyperlipidemia Prescription Drugs by Country
7.1.1 Europe Hyperlipidemia Prescription Drugs Sales by Country
7.1.2 Europe Hyperlipidemia Prescription Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hyperlipidemia Prescription Drugs Market Facts & Figures by Type
7.3 Europe Hyperlipidemia Prescription Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hyperlipidemia Prescription Drugs by Region
8.1.1 Asia Pacific Hyperlipidemia Prescription Drugs Sales by Region
8.1.2 Asia Pacific Hyperlipidemia Prescription Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hyperlipidemia Prescription Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hyperlipidemia Prescription Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hyperlipidemia Prescription Drugs by Country
9.1.1 Latin America Hyperlipidemia Prescription Drugs Sales by Country
9.1.2 Latin America Hyperlipidemia Prescription Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hyperlipidemia Prescription Drugs Market Facts & Figures by Type
9.3 Central & South America Hyperlipidemia Prescription Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hyperlipidemia Prescription Drugs by Country
10.1.1 Middle East and Africa Hyperlipidemia Prescription Drugs Sales by Country
10.1.2 Middle East and Africa Hyperlipidemia Prescription Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hyperlipidemia Prescription Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hyperlipidemia Prescription Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Hyperlipidemia Prescription Drugs Products Offered
11.1.5 Amgen Related Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Description and Business Overview
11.2.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eli Lilly Hyperlipidemia Prescription Drugs Products Offered
11.2.5 Eli Lilly Related Developments
11.3 GlaxoSmithKline Pharmaceuticals
11.3.1 GlaxoSmithKline Pharmaceuticals Corporation Information
11.3.2 GlaxoSmithKline Pharmaceuticals Description and Business Overview
11.3.3 GlaxoSmithKline Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Products Offered
11.3.5 GlaxoSmithKline Pharmaceuticals Related Developments
11.4 Isis Pharmaceuticals
11.4.1 Isis Pharmaceuticals Corporation Information
11.4.2 Isis Pharmaceuticals Description and Business Overview
11.4.3 Isis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Products Offered
11.4.5 Isis Pharmaceuticals Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Hyperlipidemia Prescription Drugs Products Offered
11.5.5 Merck Related Developments
11.6 Dr.Reddy’s Laboratories
11.6.1 Dr.Reddy’s Laboratories Corporation Information
11.6.2 Dr.Reddy’s Laboratories Description and Business Overview
11.6.3 Dr.Reddy’s Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Dr.Reddy’s Laboratories Hyperlipidemia Prescription Drugs Products Offered
11.6.5 Dr.Reddy’s Laboratories Related Developments
11.7 Immuron Limited
11.7.1 Immuron Limited Corporation Information
11.7.2 Immuron Limited Description and Business Overview
11.7.3 Immuron Limited Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Immuron Limited Hyperlipidemia Prescription Drugs Products Offered
11.7.5 Immuron Limited Related Developments
11.8 Esperion Therapeutics
11.8.1 Esperion Therapeutics Corporation Information
11.8.2 Esperion Therapeutics Description and Business Overview
11.8.3 Esperion Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Esperion Therapeutics Hyperlipidemia Prescription Drugs Products Offered
11.8.5 Esperion Therapeutics Related Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description and Business Overview
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer Hyperlipidemia Prescription Drugs Products Offered
11.9.5 Pfizer Related Developments
11.10 Formac Pharmaceuticals
11.10.1 Formac Pharmaceuticals Corporation Information
11.10.2 Formac Pharmaceuticals Description and Business Overview
11.10.3 Formac Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Products Offered
11.10.5 Formac Pharmaceuticals Related Developments
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Hyperlipidemia Prescription Drugs Products Offered
11.1.5 Amgen Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hyperlipidemia Prescription Drugs Market Estimates and Projections by Region
12.1.1 Global Hyperlipidemia Prescription Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hyperlipidemia Prescription Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hyperlipidemia Prescription Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hyperlipidemia Prescription Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hyperlipidemia Prescription Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hyperlipidemia Prescription Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hyperlipidemia Prescription Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hyperlipidemia Prescription Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hyperlipidemia Prescription Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hyperlipidemia Prescription Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hyperlipidemia Prescription Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hyperlipidemia Prescription Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hyperlipidemia Prescription Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hyperlipidemia Prescription Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hyperlipidemia Prescription Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hyperlipidemia Prescription Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hyperlipidemia Prescription Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hyperlipidemia Prescription Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hyperlipidemia Prescription Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hyperlipidemia Prescription Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hyperlipidemia Prescription Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hyperlipidemia Prescription Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hyperlipidemia Prescription Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hyperlipidemia Prescription Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hyperlipidemia Prescription Drugs Market Segments
Table 2. Ranking of Global Top Hyperlipidemia Prescription Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hyperlipidemia Prescription Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of HMG COA Reductase Inhibitors
Table 5. Major Manufacturers of Fibric Acid Derivatives
Table 6. Major Manufacturers of Nicotinic Acid
Table 7. Major Manufacturers of Bile Acid Sequestrating Agents
Table 8. Major Manufacturers of Cholesterol Absorption Inhibitors
Table 9. Major Manufacturers of Combination Drug Therapy
Table 10. Global Hyperlipidemia Prescription Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 11. Global Hyperlipidemia Prescription Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 12. Global Hyperlipidemia Prescription Drugs Sales by Regions 2015-2020 (K Units)
Table 13. Global Hyperlipidemia Prescription Drugs Sales Market Share by Regions (2015-2020)
Table 14. Global Hyperlipidemia Prescription Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Hyperlipidemia Prescription Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 16. Global Hyperlipidemia Prescription Drugs Sales Share by Manufacturers (2015-2020)
Table 17. Global Hyperlipidemia Prescription Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Hyperlipidemia Prescription Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hyperlipidemia Prescription Drugs as of 2019)
Table 19. Hyperlipidemia Prescription Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Hyperlipidemia Prescription Drugs Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Hyperlipidemia Prescription Drugs Price (2015-2020) (USD/Pcs)
Table 22. Hyperlipidemia Prescription Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Hyperlipidemia Prescription Drugs Product Type
Table 24. Date of International Manufacturers Enter into Hyperlipidemia Prescription Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 27. Global Hyperlipidemia Prescription Drugs Sales Share by Type (2015-2020)
Table 28. Global Hyperlipidemia Prescription Drugs Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Hyperlipidemia Prescription Drugs Revenue Share by Type (2015-2020)
Table 30. Hyperlipidemia Prescription Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 32. Global Hyperlipidemia Prescription Drugs Sales Share by Application (2015-2020)
Table 33. North America Hyperlipidemia Prescription Drugs Sales by Country (2015-2020) (K Units)
Table 34. North America Hyperlipidemia Prescription Drugs Sales Market Share by Country (2015-2020)
Table 35. North America Hyperlipidemia Prescription Drugs Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2015-2020)
Table 37. North America Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 38. North America Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Table 39. North America Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 40. North America Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Table 41. Europe Hyperlipidemia Prescription Drugs Sales by Country (2015-2020) (K Units)
Table 42. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Country (2015-2020)
Table 43. Europe Hyperlipidemia Prescription Drugs Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2015-2020)
Table 45. Europe Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 46. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Table 47. Europe Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 48. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Hyperlipidemia Prescription Drugs Sales by Region (2015-2020) (K Units)
Table 50. Asia Pacific Hyperlipidemia Prescription Drugs Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Hyperlipidemia Prescription Drugs Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Hyperlipidemia Prescription Drugs Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 54. Asia Pacific Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 56. Asia Pacific Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Table 57. Latin America Hyperlipidemia Prescription Drugs Sales by Country (2015-2020) (K Units)
Table 58. Latin America Hyperlipidemia Prescription Drugs Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Hyperlipidemia Prescription Drugs Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2015-2020)
Table 61. Latin America Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 62. Latin America Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Table 63. Latin America Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 64. Latin America Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Hyperlipidemia Prescription Drugs Sales by Country (2015-2020) (K Units)
Table 66. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Hyperlipidemia Prescription Drugs Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Hyperlipidemia Prescription Drugs Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Hyperlipidemia Prescription Drugs Sales by Type (2015-2020) (K Units)
Table 70. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Hyperlipidemia Prescription Drugs Sales by Application (2015-2020) (K Units)
Table 72. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Table 73. Amgen Corporation Information
Table 74. Amgen Description and Major Businesses
Table 75. Amgen Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Amgen Product
Table 77. Amgen Recent Development
Table 78. Eli Lilly Corporation Information
Table 79. Eli Lilly Description and Major Businesses
Table 80. Eli Lilly Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Eli Lilly Product
Table 82. Eli Lilly Recent Development
Table 83. GlaxoSmithKline Pharmaceuticals Corporation Information
Table 84. GlaxoSmithKline Pharmaceuticals Description and Major Businesses
Table 85. GlaxoSmithKline Pharmaceuticals Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. GlaxoSmithKline Pharmaceuticals Product
Table 87. GlaxoSmithKline Pharmaceuticals Recent Development
Table 88. Isis Pharmaceuticals Corporation Information
Table 89. Isis Pharmaceuticals Description and Major Businesses
Table 90. Isis Pharmaceuticals Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Isis Pharmaceuticals Product
Table 92. Isis Pharmaceuticals Recent Development
Table 93. Merck Corporation Information
Table 94. Merck Description and Major Businesses
Table 95. Merck Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Merck Product
Table 97. Merck Recent Development
Table 98. Dr.Reddy's Laboratories Corporation Information
Table 99. Dr.Reddy's Laboratories Description and Major Businesses
Table 100. Dr.Reddy's Laboratories Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Dr.Reddy's Laboratories Product
Table 102. Dr.Reddy's Laboratories Recent Development
Table 103. Immuron Limited Corporation Information
Table 104. Immuron Limited Description and Major Businesses
Table 105. Immuron Limited Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Immuron Limited Product
Table 107. Immuron Limited Recent Development
Table 108. Esperion Therapeutics Corporation Information
Table 109. Esperion Therapeutics Description and Major Businesses
Table 110. Esperion Therapeutics Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Esperion Therapeutics Product
Table 112. Esperion Therapeutics Recent Development
Table 113. Pfizer Corporation Information
Table 114. Pfizer Description and Major Businesses
Table 115. Pfizer Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Pfizer Product
Table 117. Pfizer Recent Development
Table 118. Formac Pharmaceuticals Corporation Information
Table 119. Formac Pharmaceuticals Description and Major Businesses
Table 120. Formac Pharmaceuticals Hyperlipidemia Prescription Drugs Production (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Formac Pharmaceuticals Product
Table 122. Formac Pharmaceuticals Recent Development
Table 123. Global Hyperlipidemia Prescription Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 124. Global Hyperlipidemia Prescription Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 125. Global Hyperlipidemia Prescription Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 126. Global Hyperlipidemia Prescription Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 127. North America: Hyperlipidemia Prescription Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 128. North America: Hyperlipidemia Prescription Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Europe: Hyperlipidemia Prescription Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 130. Europe: Hyperlipidemia Prescription Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Asia Pacific: Hyperlipidemia Prescription Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 132. Asia Pacific: Hyperlipidemia Prescription Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 133. Latin America: Hyperlipidemia Prescription Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Latin America: Hyperlipidemia Prescription Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Middle East and Africa: Hyperlipidemia Prescription Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 136. Middle East and Africa: Hyperlipidemia Prescription Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 138. Key Challenges
Table 139. Market Risks
Table 140. Main Points Interviewed from Key Hyperlipidemia Prescription Drugs Players
Table 141. Hyperlipidemia Prescription Drugs Customers List
Table 142. Hyperlipidemia Prescription Drugs Distributors List
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Hyperlipidemia Prescription Drugs Product Picture
Figure 2. Global Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. HMG COA Reductase Inhibitors Product Picture
Figure 4. Fibric Acid Derivatives Product Picture
Figure 5. Nicotinic Acid Product Picture
Figure 6. Bile Acid Sequestrating Agents Product Picture
Figure 7. Cholesterol Absorption Inhibitors Product Picture
Figure 8. Combination Drug Therapy Product Picture
Figure 9. Global Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Hyperlipidemia Prescription Drugs Report Years Considered
Figure 13. Global Hyperlipidemia Prescription Drugs Market Size 2015-2026 (US$ Million)
Figure 14. Global Hyperlipidemia Prescription Drugs Sales 2015-2026 (K Units)
Figure 15. Global Hyperlipidemia Prescription Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Hyperlipidemia Prescription Drugs Sales Market Share by Region (2015-2020)
Figure 17. Global Hyperlipidemia Prescription Drugs Sales Market Share by Region in 2019
Figure 18. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Region (2015-2020)
Figure 19. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Region in 2019
Figure 20. Global Hyperlipidemia Prescription Drugs Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Hyperlipidemia Prescription Drugs Revenue in 2019
Figure 22. Hyperlipidemia Prescription Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Hyperlipidemia Prescription Drugs Sales Market Share by Type (2015-2020)
Figure 24. Global Hyperlipidemia Prescription Drugs Sales Market Share by Type in 2019
Figure 25. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Type (2015-2020)
Figure 26. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Type in 2019
Figure 27. Global Hyperlipidemia Prescription Drugs Market Share by Price Range (2015-2020)
Figure 28. Global Hyperlipidemia Prescription Drugs Sales Market Share by Application (2015-2020)
Figure 29. Global Hyperlipidemia Prescription Drugs Sales Market Share by Application in 2019
Figure 30. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Application (2015-2020)
Figure 31. Global Hyperlipidemia Prescription Drugs Revenue Market Share by Application in 2019
Figure 32. North America Hyperlipidemia Prescription Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 33. North America Hyperlipidemia Prescription Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2019
Figure 35. North America Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2019
Figure 36. U.S. Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 37. U.S. Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 39. Canada Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Hyperlipidemia Prescription Drugs Market Share by Type in 2019
Figure 41. North America Hyperlipidemia Prescription Drugs Market Share by Application in 2019
Figure 42. Europe Hyperlipidemia Prescription Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 43. Europe Hyperlipidemia Prescription Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2019
Figure 45. Europe Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2019
Figure 46. Germany Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. Germany Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. France Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. U.K. Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. Italy Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. Russia Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Hyperlipidemia Prescription Drugs Market Share by Type in 2019
Figure 57. Europe Hyperlipidemia Prescription Drugs Market Share by Application in 2019
Figure 58. Asia Pacific Hyperlipidemia Prescription Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 59. Asia Pacific Hyperlipidemia Prescription Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Hyperlipidemia Prescription Drugs Sales Market Share by Region in 2019
Figure 61. Asia Pacific Hyperlipidemia Prescription Drugs Revenue Market Share by Region in 2019
Figure 62. China Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. China Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. Japan Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. South Korea Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. India Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Australia Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Taiwan Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Indonesia Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Thailand Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Malaysia Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Philippines Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 83. Vietnam Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Hyperlipidemia Prescription Drugs Market Share by Type in 2019
Figure 85. Asia Pacific Hyperlipidemia Prescription Drugs Market Share by Application in 2019
Figure 86. Latin America Hyperlipidemia Prescription Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 87. Latin America Hyperlipidemia Prescription Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2019
Figure 89. Latin America Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2019
Figure 90. Mexico Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 91. Mexico Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Brazil Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 95. Argentina Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Hyperlipidemia Prescription Drugs Market Share by Type in 2019
Figure 97. Latin America Hyperlipidemia Prescription Drugs Market Share by Application in 2019
Figure 98. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 99. Middle East and Africa Hyperlipidemia Prescription Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Hyperlipidemia Prescription Drugs Revenue Market Share by Country in 2019
Figure 102. Turkey Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 103. Turkey Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. Saudi Arabia Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Hyperlipidemia Prescription Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 107. U.A.E Hyperlipidemia Prescription Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Hyperlipidemia Prescription Drugs Market Share by Type in 2019
Figure 109. Middle East and Africa Hyperlipidemia Prescription Drugs Market Share by Application in 2019
Figure 110. North America Hyperlipidemia Prescription Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. North America Hyperlipidemia Prescription Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Hyperlipidemia Prescription Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Europe Hyperlipidemia Prescription Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Hyperlipidemia Prescription Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Asia Pacific Hyperlipidemia Prescription Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Hyperlipidemia Prescription Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Latin America Hyperlipidemia Prescription Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Hyperlipidemia Prescription Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Middle East and Africa Hyperlipidemia Prescription Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
処方用皮膚科薬の世界市場（～2026年） Market Analysis and Insights: Global Prescription Dermatological Drugs Market The global Prescription Dermatological Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Prescription Dermatological Drugs Scope and Mar…- コレステロール降下薬の世界市場（～2026年） Market Analysis and Insights: Global Cholesterol-Lowering Drugs Market The global Cholesterol-Lowering Drugs market size is projected to reach US$ 17960 million by 2026, from US$ 17440 million in 2020, at a CAGR of 2.8%% during 2021-2026. Global Cholesterol-Lowering Drugs Scope and Market Size Chole…
- コレステロール低下生物学的薬剤の世界市場（～2026年） The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad chol…
- 抗肥満処方の世界市場（～2026年） Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory …
- Gタンパク質結合胆汁酸受容体1の世界市場（～2026年） Market Analysis and Insights: Global G Protein Coupled Bile Acid Receptor 1 Market The global G Protein Coupled Bile Acid Receptor 1 market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global G Protein Coupled Bile Acid Receptor …